drugset
drugset / Trial / NCT01230749

A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus

NCT01230749 ↗

Phase 2 Completed 89 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the body does to the medication) and pharmacodynamics (what the medication does to the body) of treatment with JNJ-41443532 relative to treatment with placebo in type 2 diabetes mellitus participants.

Timeline

Start
2010-12
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-41443532 Small molecule 250 mg Oral
Subject JNJ-41443532 Small molecule 1000 mg Oral
Comparator Pioglitazone Small molecule 30 mg Oral

Indications

type 2 diabetes mellitus